Uterine carcinosarcomas case series of rare uterine malignancy
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250995Keywords:
Carcinosarcoma, Biphasic, Treatment, Rare neoplasiaAbstract
Primary malignant mixed Müllerian tumor (MMMT) of the ovary is a rare and highly aggressive neoplasm predominantly affecting postmenopausal women. MMMT is a biphasic tumor comprising both epithelial and mesenchymal components and is associated with significantly higher mortality compared to epithelial ovarian neoplasms. Patients typically present with symptoms such as vaginal bleeding, abdominal pain, and a palpable mass. Surgery remains the primary treatment modality, while adjuvant therapies, including chemotherapy and radiotherapy, play a crucial role in improving locoregional control and managing distant metastasis. Due to the rarity of these tumors, there is limited literature on their optimal therapeutic management. This series aims to analyse the clinical presentations and treatment outcomes of patients diagnosed with this uncommon uterine cancer treated at our hospital.
Metrics
References
El-Nashar SA, Mariani A. Uterine carcinosarcoma. Clin Obstetr Gynecol. 2011;54(2):292-304. DOI: https://doi.org/10.1097/GRF.0b013e31821ac635
Grayson W, Taylor LF, Cooper K. Carcinosarcoma of uterine cervix: a report of eight cases with immunohistochemical analysis and evaluation of human papillomavirus status. Am J Surg Pathol. 2001;25(3):338-47.
Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky P, Finkelstein SD. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol. 1998;29(1):82-7. DOI: https://doi.org/10.1016/S0046-8177(98)90394-X
Tanaka YO, Tsunoda H, Minami R, Yoshikawa H, Minami M. Carcinosarcoma of the uterus: MR findings. J Magnetic Resonance Imaging. 2008;28(2):434-9. DOI: https://doi.org/10.1002/jmri.21469
Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, et al. Mixed Mullerian Tumors of the Ovary: Experience with Cytoreductive Surgery and Platinum-Based Combination Chemotherapy. Int J Gynarcol Cancer. 2006;16(1):101-5. DOI: https://doi.org/10.1111/j.1525-1438.2006.00281.x
Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role for the epithelial component and the conversion theory of histogenesis. Am J Surgical Pathol. 1995;19(6):666-74. DOI: https://doi.org/10.1097/00000478-199506000-00007
Jin Z, Ogata S, Tamura G. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecolog Pathol. 2003;22(4):368-73. DOI: https://doi.org/10.1097/01.pgp.0000092134.88121.56
Grayson W, Taylor LF, Cooper K. Carcinosarcoma of uterine cervix: a report of eight cases with immunohistochemical analysis and evaluation of human papillomavirus status. Am J Surg Pathol. 2001;25(3):338-47. DOI: https://doi.org/10.1097/00000478-200103000-00008
Raspollini MR, Susini T, Amunni G, Milena P, Antonio T, Mauro M, et al. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol. 2005;96(1):159-67. DOI: https://doi.org/10.1016/j.ygyno.2004.09.050
Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci. 2003;94(11):986-91. DOI: https://doi.org/10.1111/j.1349-7006.2003.tb01389.x
Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, et al. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecologic Oncol. 1996;60(1):81-8. DOI: https://doi.org/10.1006/gyno.1996.0015
Vorgias G, Fotiou S. The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstetr. 2010;282(6):659-64. DOI: https://doi.org/10.1007/s00404-010-1649-0
Brown L. Pathology of uterine malignancies. Clin Oncol. 2008;20(6):433-47. DOI: https://doi.org/10.1016/j.clon.2008.04.005
Homesley HD, Filiaci V, Markman M, Pincas B, Lynne E, Larry CK, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a gynecologic oncology group study. J Clin Oncol. 2007;25(5):526-31. DOI: https://doi.org/10.1200/JCO.2006.06.4907
Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, DeGeest K, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. J Clin Oncol. 2010;28(16):2727-31. DOI: https://doi.org/10.1200/JCO.2009.26.8326
Gunther JR, Christensen EN, Allen PK, Ramondetta LM, Jhingran A, Fleming ND, et al. Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. Int J Gynecol Cancer. 2018;28(1):114-21. DOI: https://doi.org/10.1097/igc.0000000000001135
Bosquet JS, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, et al. The impact of multimodal therapy on survival for uterine carcinosarcoma Gynec Oncol. 2010;116(3):419-23. DOI: https://doi.org/10.1016/j.ygyno.2009.10.053
Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Sur Pathol. 2007;31(11):1653-61. DOI: https://doi.org/10.1097/PAS.0b013e3181161ba3
Downloads
Published
How to Cite
Issue
Section
